Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19

Adeola Fowotade, Folasade Bamidele, Boluwatife Egbetola, Adeniyi Francis Fagbamigbe, Babatunde Ayodeji Adeagbo, Bolanle Olufunlola Adefuye, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Adedeji Onayade, Oluseye Oladotun Bolaji, Steve Rannard, Christian Happi, Andrew Owen, Adeniyi Olagunju
doi: https://doi.org/10.1101/2022.02.03.22270152

Article Information

doi 
https://doi.org/10.1101/2022.02.03.22270152
History 
  • February 4, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Adeola Fowotadea,
  2. Folasade Bamidelea,
  3. Boluwatife Egbetolab,
  4. Adeniyi Francis Fagbamigbec,
  5. Babatunde Ayodeji Adeagbod,
  6. Bolanle Olufunlola Adefuyeb,
  7. Ajibola Olagunoyee,
  8. Temitope Olumuyiwa Ojof,
  9. Akindele Olupelumi Adebiyig,
  10. Omobolanle Ibitayo Olagunjuh,
  11. Olabode Taiwo Ladipoi,
  12. Abdulafeez Akinloyed,
  13. Adedeji Onayadef,
  14. Oluseye Oladotun Bolajid,
  15. Steve Rannardj,
  16. Christian Happik,
  17. Andrew Owenl and
  18. Adeniyi Olagunjul,*
  1. aDepartment of Medical Microbiology and Parasitology, University of Ibadan, Ibadan, Nigeria
  2. bOlabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria
  3. cDepartment of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
  4. dDepartment of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile-Ife, Nigeria
  5. eState Specialist Hospital, Osogbo, Nigeria
  6. fDepartment of Community Health, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria
  7. gDepartment of Community Medicine, University of Ibadan, Ibadan, Nigeria
  8. hDepartment of Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Nigeria
  9. iOyo State Ministry of Health, Ibadan, Nigeria
  10. jDepartment of Chemistry, University of Liverpool, United Kingdom
  11. kAfrican Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede, Nigeria
  12. lDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
  1. ↵*Corresponding author: Adeniyi Olagunju, PhD, Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom. Tel: +44 (0)151 795 7129. Email: olagunju{at}liverpool.ac.uk.
Back to top
Posted February 04, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19
Adeola Fowotade, Folasade Bamidele, Boluwatife Egbetola, Adeniyi Francis Fagbamigbe, Babatunde Ayodeji Adeagbo, Bolanle Olufunlola Adefuye, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Adedeji Onayade, Oluseye Oladotun Bolaji, Steve Rannard, Christian Happi, Andrew Owen, Adeniyi Olagunju
medRxiv 2022.02.03.22270152; doi: https://doi.org/10.1101/2022.02.03.22270152
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area